Reports Q3 revenue $15,000, consensus $55,140. “The three potential biomarker paths that could be leveraged to increase the persuasiveness of our ALS data, as outlined by the FDA, include: the NfL analysis of our ongoing NIH-sponsored Expanded Access Program; additional ALS disease-specific biomarker changes from the HEALEY ALS Platform Trial; and NfL analysis of subjects in the open-label extension of the HEALEY ALS Platform Trial who were initially treated with placebo during the placebo-controlled portion of the trial and then received CNM-Au8 during the OLE,” said Rob Etherington, President and CEO of Clene (CLNN). “The Company anticipates completing these data analyses shortly which could support the filing of an NDA using the accelerated approval pathway.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLNN:
- Buy Rating for Clene’s CNM-Au8 Driven by Promising ALS Treatment Potential and Market Interest
- Is CLNN a Buy, Before Earnings?
- Clene’s CNM-Au8: A Promising Candidate in ALS Treatment with Buy Rating from Justin Walsh
- Clene’s CNM-Au8: A Promising Game-Changer in ALS Treatment with Buy Rating from Justin Walsh
- Clene Enters Equity Distribution Agreement with Canaccord